Sellas Life Sciences to Receive $23.6 Million From Exercise of Warrants
MT Newswires Live
Sep 11, 2025
Sellas Life Sciences Group (SLS) said Thursday it will receive gross proceeds of about $23.6 million from the exercise of existing warrants held by an institutional investor.
In consideration for the exercise of the warrants, the investor will receive new unregistered warrants to buy up to about 19.7 million shares and an exercise price of $1.88 per share, the company said,
The new warrants will be exercisable immediately and will expire five years and six months from the date of issuance, the company said.
The transaction is expected to close on or about Friday.
Sellas shares were down by more than 6% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.